Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.
Start | Author Index

331.O2.6 Pathophysiology of Thrombosis II

Monday, December 8, 2008: 1:30 PM-3:00 PM
3006-3008 - West (Moscone Center)
Moderators:
Donald L Yee, MD and Anne Mcleod, MD, FRCPC
1:30 PM
523
Microalbuminuria Is Associated with An Increased Risk of Venous Thromboembolism. A Novel Risk Marker for Venous ThromboembolismClinically Relevant Abstract

Bakhtawar Khan Mahmoodi1*, Ron T. Gansevoor2*, Nic J.G.M. Veeger1*, Hans L. Hillege3*, Gerjan Navis2* and Jan van der Meer1*

1Division of Hemostasis, Thrombosis and Rheology, Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
2Department of Nephrology, University Medical Center Groningen, Groningen, Netherlands
3Trial Coordination Center, Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands
1:45 PM
524
Validation of a Predictive Model for Indentifying An Increased Risk for  Thromboembolism in Children with Acute Lymphoblastic Leukemia: Results of a Multicenter Cohort Study

Silke Flege1*, Lesley Mitchell, MSc2, Gili Kenet3, Christine Heller4*, Michael Fruhwald1* and Ulrike Nowak-Gottl, MD5

1Ped. Hematol/Oncol, Univ. of Munster, Munster, Germany
2UAB/Stollery Children's Hosp., Edmonton, AB, Canada
3The Israel National Haemophilia Centre, Sheba Medical Centre, Tel Hashomer, Israel
4Ped. Hematol/Oncol, Univ. Hospital Frankfurt, Frankfurt, Germany
5Dept. of Pediatric Hem./Onc., University Children's Hospital, Munster, Germany
2:00 PM
525
Serial D-Dimer Measurements Are Useful in Predicting the Recurrence of Venous Thromboembolism after Discontinuation of AnticoagulationClinically Relevant Abstract

Montserrat Briz*, Helen Marr*, Kate Talks*, John Hanley* and Patrick Kesteven*

Haemostasis and Thrombosis, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
2:15 PM
526
Rates of Venous Thromboembolism in Commercially Insured US Surgical PatientsClinically Relevant Abstract

Alex Spyropoulos, MD, FACP, FCCP1*, Mohamed Hussein, Ms.C.S., M.S.P.H, Ph.D.2*, Jay Lin, PhD, MBA3* and David Battleman, MD2*

1Lovelace Medical Center, Clinical Thrombosis Center, Albuquerque, NM
2Health Economics and Outcomes Research, IMS Health, Falls Church, VA
3Sanofi-Aventis US, Inc., Bridgewater, NJ
2:30 PM
527
In a Prospective Inceptional Cohort Study of Children with Thrombosis, a Persistently Positive Dilute Russell Viper Venom Time Is Associated with Thrombus Progression or Recurrence and Multiple Antiphospholipid AntibodiesClinically Relevant Abstract

Hannah A Hathaway, BA*, Emily L. Joachim*, Linda Jacobson, MT*, Chris G. Bombardier, BS*, Neil A Goldenberg, MD, PhD, William E. Hathaway, MD* and Marilyn J. Manco-Johnson, MD

Pediatrics and Mountain States Regional Hemophilia & Thrombosis Center, University of Colorado Denver and The Children's Hospital, Aurora, CO
2:45 PM
528
Direct Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Formation in Human Plasma by Interfering with the Thrombin–Thrombomodulin–Protein C SystemClinically Relevant Abstract

Elisabeth Perzborn, PhD* and Michaela Harwardt*

Bayer Healthcare AG, Wuppertal, Germany
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH